|
Market Closed -
Nasdaq
23:00:00 14/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.2179 USD | +5.52% |
|
-6.48% | -56.24% |
| Market Cap | 12.41M 10.72M 10.07M 9.16M 17.23M 1.19B 17.51M 118M 46.15M 594M 46.6M 45.59M 1.98B | P/E 2026 * |
21.8x | P/E 2027 * | 3.11x |
|---|---|---|---|---|---|
| Enterprise Value | 12.41M 10.72M 10.07M 9.16M 17.23M 1.19B 17.51M 118M 46.15M 594M 46.6M 45.59M 1.98B | EV / Sales 2026 * |
0.15x | EV / Sales 2027 * | 0.11x |
| Free-Float |
63.51% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +5.52% | ||
| 1 week | -6.48% | ||
| Current month | +1.07% | ||
| 1 month | -21.76% | ||
| 3 months | -27.75% | ||
| 6 months | -43.15% | ||
| Current year | -56.24% |
| 1 week | 0.2 | 0.25 | |
| 1 month | 0.18 | 0.28 | |
| Current year | 0.16 | 0.59 | |
| 1 year | 0.16 | 1.32 | |
| 3 years | 0.16 | 2.05 | |
| 5 years | 0.16 | 150 | |
| 10 years | 0.16 | 312.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Grigorios Siokas
CEO | Chief Executive Officer | 60 | 26/02/2016 |
Georgios Terzis
DFI | Director of Finance/CFO | 43 | 11/11/2020 |
| Chief Operating Officer | 56 | 01/02/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 13/01/2014 | |
Grigorios Siokas
CHM | Chairman | 60 | 26/02/2016 |
John Hoidas
BRD | Director/Board Member | 59 | 18/11/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/30/26 A | Buy | Chief Executive Officer | 349,825 | 1.1578% | ||
| 7/29/26 A | Free | Chief Financial Officer | 328,407 | 1.0869% | ||
| 7/29/26 A | Buy | Chief Executive Officer | 766,284 | 2.5362% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +5.52% | -6.48% | -75.66% | -83.24% | 12.41M | ||
| +1.44% | -0.07% | +29.11% | +101.67% | 101B | ||
| +1.70% | -0.52% | +57.19% | +159.66% | 54.69B | ||
| 0.00% | 0.00% | +4.93% | +272.50% | 24.3B | ||
| -1.13% | -0.66% | -11.80% | -15.66% | 8.24B | ||
| +0.54% | +2.52% | -30.90% | -25.61% | 7.73B | ||
| -0.24% | -1.53% | -14.67% | -21.04% | 6.64B | ||
| +1.24% | +2.26% | +8.86% | +18.90% | 6.33B | ||
| +0.31% | -1.34% | -2.99% | +14.06% | 4.98B | ||
| -0.59% | +1.40% | -5.24% | -7.13% | 3.74B | ||
| Average | +0.88% | -1.21% | -4.12% | +41.41% | 21.8B | |
| Weighted average by Cap. | +1.10% | -0.33% | +26.54% | +116.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 84.3M 72.81M 68.42M 62.22M 117M 8.06B 119M 802M 313M 4.04B 317M 310M 13.41B | 111M 95.7M 89.93M 81.78M 154M 10.59B 156M 1.05B 412M 5.31B 416M 407M 17.63B |
| Net income | - | - |
| Net Debt | - | - |
Employees
163
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | $0.2179 | +5.52% | 953,969 |
| 13/08/26 | $0.2065 | -0.29% | 1,406,018 |
| 12/08/26 | $0.2071 | -5.78% | 1,961,585 |
| 11/08/26 | $0.2198 | -1.66% | 1,890,531 |
| 10/08/26 | $0.2235 | -4.08% | 3,862,758 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COSM Stock
Select your edition
All financial news and data tailored to specific country editions
















